The frequency of vascular events and evolution to myelofibrosis (MF) in young individuals with essential thrombocythemia (ET) is not well known. The incidence and predisposing factors to such ...

The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy. A second phase 3 clinical trial has been ...

Risk stratification replaces “Stage 4” terminology, prioritizing prevention of arterial/venous thrombosis and bleeding events over tumor burden concepts. Diagnostic confirmation typically integrates ...

Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by an increase in the number of platelets in the blood. Of the three main types of MPNs (ET, polycythemia ...

• Hgb > 18.5 g/dl (men) or > 16.5 g/dl (women) or Hgb or Hct > 99th percentile of method-specific reference range for age, sex or altitude of residence or Hgb > 17 g/dl (men) or > 15 g/dl (women) if ...

The essential thrombocythemia market is expected to grow steadily due to increasing disease prevalence, advancements in targeted therapies, and rising awareness. The development of JAK inhibitors and ...

Hemorrhagic events post-diagnosis in patients with ET significantly increase mortality risk, more than thrombosis or disease progression. Intracranial hemorrhage is the most lethal bleeding ...

New findings from a small study are suggesting that time to leukemic transformation may be driven by distinct time-dependent molecular mechanisms. While polycythemia vera (PV) and essential ...

Prof. Dr. C. Dame reports on the also relevant familial forms of essential thrombocythemia which we have not mentioned for reasons of space. These forms are naturally also to be included in the ...

Polycythemia vera and essential thrombocythemia are the most common chronic myeloproliferative neoplasms; their molecular basis has been appreciated only recently and is briefly discussed in this ...